Lung Cancer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: non small cell lung cancer diagnosed adenocarcinoma having Ex19 mutation, Ex.21 mutation, uncommon mutation using afatinib as first line treatment ECOG PS 0,1 healthy patient It is expected to survive for at least 3 months. writing consent is obtained
Exclusion criteria
Exclusion criteria: Illegal disorders such as idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug pneumonia, etc. are complicated synchronous or allochronic malignancies having the history of preoperative anticancer treatments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of pharmacological markers and resistance factors of afatinib using exosome-derived molecules | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between various factors and response rate, disease control ratio, progression-free survival time, overall survival time Consideration of compatibility of results between serum specimen and serum exosome specimen | — |
Countries
Japan
Contacts
Teikyo University School of Medicine Surgery